NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.…
INEO Appoints David Wambeke to Board of Directors
NeuroOne Medical Technologies (NASDAQ: NMTC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 0.6521 USD on 20 November 2026, down 84.6% over 52 weeks. Its 52-week range is 0.6101 USD to 6.120 USD: the price is 89.3% below the high and 6.9% above the low.
Its market capitalisation is 5.94M USD.
NeuroOne Medical Technologies reports return on equity of -51.0%, an operating margin of -63.4% and revenue up 16.3% year over year.
It holds more cash than debt, a net cash position of 1.87M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 15 December 2026.